Trial of Raltitrexed in Advanced Small-Cell Lung Cancer
Author Information
Author(s): PJ Woll, R Basser, T Le Chevalier, P Drings, G Perez Manga, A Adenis, L Seymour, F Smith, N Thatcher
Primary Institution: CRC Department of Medical Oncology, Christie Hospital, Manchester, UK
Hypothesis
Is raltitrexed effective as a second-line therapy for advanced small-cell lung cancer?
Conclusion
Raltitrexed is inactive as a second-line therapy for advanced small-cell lung cancer.
Supporting Evidence
- All patients had extensive disease and 17 had received prior therapy.
- No objective tumour response was documented.
- Only one of ten patients who received alternative cytotoxic regimens showed a response.
- The median time to progression was 6 weeks.
- The median survival from study entry was 15 weeks.
Takeaway
The study tested a drug called raltitrexed on patients with a type of lung cancer, but it didn't help them get better.
Methodology
Patients with advanced small-cell lung cancer received raltitrexed at a dose of 3 mg/m² as an intravenous infusion every 21 days.
Limitations
The study included only patients with chemoresistant disease, which may limit the generalizability of the results.
Participant Demographics
21 patients, 16 male and 5 female, median age 59 years.
Statistical Information
Confidence Interval
96% certainty that the response rate is < 20%
Want to read the original?
Access the complete publication on the publisher's website